Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study.
Munaza RiazSteven M SmithEric A DietrichDavid E WinchesterJingchuan GuoHaesuk ParkPublished in: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2024)
Among individuals with private or Medicare Advantage insurance plans, there was no significant difference in the risk of HF-related hospitalization or all-cause hospitalization between adults with HFpEF who received SAC/VAL and those who received ARB therapy.